Primer | Published:

Invasive candidiasis

Nature Reviews Disease Primers volume 4, Article number: 18026 (2018) | Download Citation


Invasive candidiasis is an important health-care-associated fungal infection that can be caused by several Candida spp.; the most common species is Candida albicans, but the prevalence of these organisms varies considerably depending on geographical location. The spectrum of disease of invasive candidiasis ranges from minimally symptomatic candidaemia to fulminant sepsis with an associated mortality exceeding 70%. Candida spp. are common commensal organisms in the skin and gut microbiota, and disruptions in the cutaneous and gastrointestinal barriers (for example, owing to gastrointestinal perforation) promote invasive disease. A deeper understanding of specific Candida spp. virulence factors, host immune response and host susceptibility at the genetic level has led to key insights into the development of early intervention strategies and vaccine candidates. The early diagnosis of invasive candidiasis is challenging but key to the effective management, and the development of rapid molecular diagnostics could improve the ability to intervene rapidly and potentially reduce mortality. First-line drugs, including echinocandins and azoles, are effective, but the emergence of antifungal resistance, especially among Candida glabrata, is a matter of concern and underscores the need to administer antifungal medications in a judicious manner, avoiding overuse when possible. A newly described pathogen, Candida auris, is an emerging multidrug-resistant organism that poses a global threat.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370, 1198–1208 (2014).

  2. 2.

    & Invasive candidiasis. J. Infect. Dis. Clin. North Am. 30, 103–124 (2016).

  3. 3.

    et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37, 634–643 (2003).

  4. 4.

    & Invasive candidiasis. N. Engl. J. Med. 373, 1445–1456 (2015).

  5. 5.

    et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309–176 (2004).

  6. 6.

    et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE 10, e0120452 (2015). This is a population-based review documenting the worldwide trend of changing epidemiology, emergence of multidrug resistance owing to echinocandin-resistant C. glabrata and the importance of stringent infection control.

  7. 7.

    , & Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 13 e1006290 (2017). This is the first review to describe the worldwide emergence of C. auris.

  8. 8.

    et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 64, 134–140 (2017).

  9. 9.

    & Emergence of Candida auris: an international call to arms. Clin. Infect. Dis. 64, 141–143 (2017).

  10. 10.

    , , & Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRy antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 85, 200–204 (2016).

  11. 11.

    , , , & Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program J. Clin. Microbiol. 49, 396–399 (2011).

  12. 12.

    et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014. Open Forum Infect. Dis. 2, ofv163 (2015).

  13. 13.

    & Echinocandin resistance: an emerging clinical problem? Curr. Opin. Infect. Dis. 27 484–492 (2014).

  14. 14.

    et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56, 1724–1732 (2013).

  15. 15.

    et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302, 2323–2329 (2009).

  16. 16.

    et al. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med. 35, 2141–2145 (2009).

  17. 17.

    et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26, 271–276 (2007).

  18. 18.

    , , , & Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerg. Infect. Dis. 23, 7–13 (2016).

  19. 19.

    et al. Role of Dectin-2 for host defense against systemic infection with Candida glabrata. Infect. Immun. 82, 1064–1673 (2014).

  20. 20.

    , , & The role of galectin-3 in phagocytosis of Candida albicans and Candida parapsilosis by human neutrophils. Cell. Microbiol. 15, 1127–1142 (2013).

  21. 21.

    , , & Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat. Rev. Microbiol. 10 112–122 (2011).

  22. 22.

    , , , & Immune defence against Candida fungal infections. Nat. Rev. Immunol. 15, 630–642 (2015).

  23. 23.

    et al. Activation of HIF-1alpha and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat. Med. 21, 808–814 (2015).

  24. 24.

    & Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog. 9, e1003079 (2013).

  25. 25.

    & Mendelian genetics of human susceptibility to fungal infection. Cold Spring Harb. Perspect. Med. 4 a019638 (2014).

  26. 26.

    et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr. Opin. Allergy Clin. Immunol. 12, 616–622 (2012).

  27. 27.

    et al. Nonfilamentous C. albicans mutants are avirulent. Cell 90, 939–949 (1997).

  28. 28.

    et al. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans EMBO J. 20, 4742–4752 (2001).

  29. 29.

    et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Invest. 116, 1642–1650 (2006).

  30. 30.

    et al. Differential adaptation of Candida albicans in vivo modulates immune recognition by dectin-1. PLoS Pathog. 9, e1003315 (2013).

  31. 31.

    , , , Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog. 4, e1000227 (2008).

  32. 32.

    et al. Candida albicans hyphal formation and the expression of the Efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infect. Immun. 70, 3689–3700 (2002).

  33. 33.

    et al. In vivo induction of neutrophil chemotaxis by secretory aspartyl proteinases of Candida albicans. Virulence 7, 819–825 (2016).

  34. 34.

    et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature 532, 64–68 (2016).

  35. 35.

    & Host cell invasion by medically important fungi. Cold Spring Harb. Perspect. Med. 5, a019687 (2014).

  36. 36.

    et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol. 5, e64 (2007).

  37. 37.

    et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 30, 7594–7600 (2012).

  38. 38.

    et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis; a phase 2 randomized, double-blind, placebo controlled trial. Clin. Infect. Dis. (2018).

  39. 39.

    & Fungal biofilms drug resistance and recurrent infection. Cold Spring Harb. Perspect. Med. 4 a019729 (2014).

  40. 40.

    et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148, 126–138 (2012).

  41. 41.

    , , , & Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei. Antimicrob. Agents Chemother. 58, 3550–3552 (2014).

  42. 42.

    et al. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56, 2435–2442 (2012).

  43. 43.

    , , & Molecular basis of antifungal drug resistance in yeasts. Int. J. Antimicrob. Agents. 50, 599–606 (2017).

  44. 44.

    et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J. Antimicrob. Chemother. 70, 2551–2555 (2015).

  45. 45.

    et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat. Commun. 7, 11128 (2016). This is the first description of the potential role of the DNA mismatch repair gene MSH2 in facilitating drug resistance in C. glabrata. In vitro and in vivo (mouse model) experimentation demonstrate an increased rate of drug resistance in MSH2 mutants and that MSH2 mutants are found among clinical isolates. The potential role in clinical epidemiology remains to be clarified.

  46. 46.

    , & Drug-resistant Candida glabrata infection in cancer patients. Emerg. Infect. Dis. 20, 1833–1840 (2014).

  47. 47.

    Innate antifungal immunity: the key role of phagocytes. Annu. Rev. Immunol. 29, 1–21 (2011).

  48. 48.

    & Interactions of fungal pathogens with phagocytes. Nat. Rev. Microbiol. 14, 163–176 (2016).

  49. 49.

    & C-Type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13, 817–822 (2012).

  50. 50.

    et al. The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. Eur. J. Clin. Microbiol. Infect. Dis. 34, 963–974 (2015).

  51. 51.

    , & Immunity to fungi. Curr. Opin. Immunol. 24, 449–458 (2012).

  52. 52.

    New insights into innate immune control of systemic candidiasis. Med. Mycol. 52, 555–564 (2014).

  53. 53.

    , , & An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6, 67–78 (2008).

  54. 54.

    et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat. Immunol. 13, 246–254 (2012).

  55. 55.

    et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459, 433–436 (2009).

  56. 56.

    et al. Cutting edge: Nlrp10 is essential for protective antifungal adaptive immunity against Candida albicans J. Immunol. 189, 4713–4717 (2012).

  57. 57.

    et al. Complement plays a central role in Candida albicans-induced cytokine production by human PBMCs. Eur. J. Immunol. 42, 993–1004 (2012).

  58. 58.

    et al. Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J. Immunol. 177, 4679–4687 (2006).

  59. 59.

    et al. C-Type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity 39, 324–334 (2013).

  60. 60.

    , , & Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur. J. Immunol. 39, 1379–1386 (2009).

  61. 61.

    et al. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses. Nat. Immunol. 16, 642–652 (2015).

  62. 62.

    et al. Phospholipase Cgamma2 (PLCgamma2) is key component in Dectin-2 signaling pathway, mediating anti-fungal innate immune responses. J. Biol. Chem. 286, 43651–43659 (2011).

  63. 63.

    et al. Syk kinase-coupled C-type lectin receptors engage protein kinase C-sigma to elicit Card9 adaptor-mediated innate immunity. Immunity 36, 32–42 (2012).

  64. 64.

    et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. J. Exp. Med. 211, 2307–2321 (2014).

  65. 65.

    & Mechanistic insights into the role of C-type lectin receptor/CARD9 signaling in human antifungal immunity. Front. Cell. Infect. Microbiol. 6, 39 (2016).

  66. 66.

    et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J. Allergy Clin. Immunol. 135, 1558–1568.e2 (2015).

  67. 67.

    et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321, 691–696 (2008).

  68. 68.

    & Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 63, 243–273 (1984).

  69. 69.

    et al. Homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361, 1727–1735 (2009). This study is the first to describe CARD9 deficiency as a primary immunodeficiency that results in fungal-specific infection susceptibility to mucosal candidiasis and invasive candidiasis that specifically involves the central nervous system.

  70. 70.

    et al. CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. PLoS Pathog. 11, e1005293 (2015).

  71. 71.

    et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361, 1760–1767 (2009).

  72. 72.

    et al. An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J. Immunol. 158, 2356–2362 (1997).

  73. 73.

    , , & Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin. Infect. Dis. 32, 1713–1717 (2001).

  74. 74.

    , , & Organ-specific innate immune responses in a mouse model of candidiasis. J. Innate Immun. 3, 180–199 (2011).

  75. 75.

    et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416, 291–297 (2002).

  76. 76.

    , , , & Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 79, 170–200 (2000).

  77. 77.

    & Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J. Clin. Invest. 48, 1478–1488 (1969).

  78. 78.

    , , & Calcineurin regulates innate antifungal immunity in neutrophils. J. Exp. Med. 207, 923–931 (2010).

  79. 79.

    et al. The beta-glucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to promote Candida albicans clearance. Cell Host Microbe 10, 603–615 (2011).

  80. 80.

    Measurement of candidacidal activity of specific leukocyte types in mixed cell populations I. Normal, myeloperoxidase-deficient, and chronic granulomatous disease neutrophils. Infect. Immun. 2, 42–47 (1970).

  81. 81.

    et al. CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. Sci. Transl Med. 8, 322ra310 (2016).

  82. 82.

    et al. Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense. Nat. Genet. 46, 1028–1033 (2014).

  83. 83.

    , , , & How neutrophils kill fungi. Immunol. Rev. 273, 299–311 (2016).

  84. 84.

    et al. Two independent killing mechanisms of Candida albicans by human neutrophils: evidence from innate immunity defects. Blood 124, 590–597 (2014).

  85. 85.

    et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin. Infect. Dis. 46, 696–702 (2008).

  86. 86.

    & Candida-associated renal papillary necrosis. Am. J. Clin. Pathol. 75, 190–194 (1981).

  87. 87.

    et al. CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J. Clin. Invest. 123, 5035–5051 (2013). This study is the first to describe the role of CX3C-chemokine receptor 1 (CX3CR1)-expressing resident macrophages in host defence against invasive candidiasis and to identify the dysfunctional CX3CR1-M280 allele as a risk factor for candidaemia and disseminated candidiasis in humans.

  88. 88.

    et al. Autophagy enhances NFkappaB activity in specific tissue macrophages by sequestering A20 to boost antifungal immunity. Nat. Commun. 6, 5779 (2015).

  89. 89.

    et al. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J. Infect. Dis. 209, 109–119 (2014).

  90. 90.

    et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223–232 (2012).

  91. 91.

    et al. Batf3-dependent CD103+ dendritic cell accumulation is dispensable for mucosal and systemic antifungal host defense. Virulence 7, 826–835 (2016).

  92. 92.

    et al. Interferon-beta production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity 38, 1176–1186 (2013).

  93. 93.

    et al. Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes Infect. 6, 985–989 (2004).

  94. 94.

    et al. Syk signaling in dendritic cells orchestrates innate resistance to systemic fungal infection. PLoS Pathog. 10, e1004276 (2014).

  95. 95.

    , , , & IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40, 117–127 (2014).

  96. 96.

    et al. Effect of Granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV Trial. J. Clin. Oncol. 33, 3999–4006 (2015).

  97. 97.

    et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin. Infect. Dis. 54, 502–510 (2012).

  98. 98.

    et al. Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nat. Commun. 5, 4675 (2014). This study is the first genome-wide analysis of genetic variants that may confer susceptibility to candidaemia, and it identifies new immunogenetic risk factors for the infection in the ICU.

  99. 99.

    et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 205, 934–943 (2012).

  100. 100.

    et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat. Commun. 4, 1342 (2013).

  101. 101.

    et al. Polymorphisms in tumor necrosis factor-alpha increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*. Crit. Care Med. 42, e304–e308 (2014).

  102. 102.

    et al. Host response to fungal infections - how immunology and host genetics could help to identify and treat patients at risk. Swiss Med. Wkly 146, w14350 (2016).

  103. 103.

    , & Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49, 3640–3645 (2005).

  104. 104.

    et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43, 25–31 (2006).

  105. 105.

    et al. Ocular manifestations of candidemia. Clin. Infect. Dis. 53, 262–268 (2011)

  106. 106.

    et al. Clinical Practice Guideline for the Management of Candidiasis: update by the Infectious Diseases Society of America. Clin. Infect. Dis. 62 1–50 (2016). This is the most recent version of international treatment guidelines for candidaemia and invasive candidiasis.

  107. 107.

    et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18, 19–37 (2012).

  108. 108.

    & Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin. Infect. Dis. 56, 1284–1292 (2013). This is an excellent overview of the strengths and limitations for current diagnostics.

  109. 109.

    et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin. Microbiol. Infect. 18, 9–18 (2012).

  110. 110.

    et al. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. 47, 1030–1045 (2012). This is a European guideline on classical diagnostics; it summarizes the diagnostic options and, importantly, how to improve the sensitivity of the classical techniques.

  111. 111.

    et al. Quantitation of Candida CFU in initial positive blood cultures. J. Clin. Microbiol. 49, 2879–2883 (2011).

  112. 112.

    et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J. Clin. Microbiol. 49, 3300–3308 (2011).

  113. 113.

    , , , & Cumitech 1C, Blood Cultures IV American Society for Microbiology, 2005).

  114. 114.

    et al. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J. Clin. Microbiol. 42, 115–118 (2004).

  115. 115.

    , , & Clinical comparison of the Bactec Mycosis IC/F, BacT/Alert FA, and BacT/Alert FN blood culture vials for the detection of candidemia. Diagn. Microbiol. Infect. Dis. 73, 153–156 (2012).

  116. 116.

    et al. Impact of yeast-bacteria coinfection on the detection of Candida sp. in an automated blood culture system. Diagn. Microbiol. Infect. Dis. 72, 328–331 (2012).

  117. 117.

    , , , & Risk factors for hospital-acquired candidemia. A matched case-control study. Arch. Intern. Med. 149, 2349–2353 (1989).

  118. 118.

    , , , & Typing of Candida isolates from patients with invasive infection and concomitant colonization. Scand. J. Infect. Dis. 42, 109–113 (2010).

  119. 119.

    et al. Posttreatment antifungal resistance among colonizing Candida isolates in Candidemia patients: results from a systematic multicenter study. Antimicrob. Agents Chemother. 60, 1500–1508 (2016).

  120. 120.

    et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. J. Clin. Microbiol. 53, 1324–1330 (2015).

  121. 121.

    , , , & Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220, 751–758 (1994).

  122. 122.

    et al. Empirical Micafungin treatment and survival without invasive fungal infection in adults with ICU-Acquired sepsis, candida colonization, and multiple organ failure. JAMA 316, 1555 (2016).

  123. 123.

    , , , & Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin. Microbiol. Infect. 15, 380–386 (2009).

  124. 124.

    et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J. Med. Microbiol. 51, 433–442 (2002).

  125. 125.

    , , , & The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the third European conference on infections in leukemia. Crit. Care 14, R222 (2010).

  126. 126.

    et al. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses 59, 374–378 (2016).

  127. 127.

    et al. Detection of candidaemia in patients with and without underlying haematological disease. Clin. Microbiol. Infect. 16, 855–862 (2010).

  128. 128.

    , , , & Experience with the Platelia Candida ELISA for the diagnosis of invasive candidosis in neonatal patients. Clin. Microbiol. Infect. 14, 391–393 (2008).

  129. 129.

    et al. Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of saving Candida meningitis. J. Clin. Microbiol. 42, 867–870 (2004).

  130. 130.

    , , , & Culture-negative Candida meningitis diagnosed by detection of Candida mannan antigen in CSF. Neurology 81, 1555–1556 (2013).

  131. 131.

    et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit. Care 20, 149 (2016).

  132. 132.

    et al. Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin. Microbiol. Infect. 19, 39–49 (2013).

  133. 133.

    et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin. Infect. Dis. 52, 750–770 (2011).

  134. 134.

    et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS ONE 7, e42282 (2012).

  135. 135.

    et al. β-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am. J. Respir. Crit. Care Med. 188, 1100–1109 (2013).

  136. 136.

    et al. A retrospective assessment of four antigen assays for the detection of invasive candidiasis among high-risk hospitalized patients. Myopathologia (2018).

  137. 137.

    et al. Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J. Clin. Microbiol. 49, 58–61 (2011).

  138. 138.

    et al. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. J. Antimicrob. Chemother. 70, 3107–3115 (2015).

  139. 139.

    et al. Combined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Crit. Care 21, 176 (2017).

  140. 140.

    et al. Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies—high frequency of false-positive results and their analysis. J. Med. Microbiol. 59, 1016–1022 (2010).

  141. 141.

    et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. J. Antimicrob. Chemother. 69, 3134–3141 (2014).

  142. 142.

    et al. Candida albicans germ-tube antibody: evaluation of a new automatic assay for diagnosing invasive Candidiasis in ICU patients. Mycopathologia 182, 645–652 (2017).

  143. 143.

    et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) C. Clin. Infect. Dis. 46, 1813–1821 (2008).

  144. 144.

    et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS ONE 8, e62323 (2013).

  145. 145.

    et al. Evaluation of the broad-range PCR/ESI-MS technology in blood specimens for the molecular diagnosis of bloodstream infections. PLoS ONE 10, e0140865 (2015).

  146. 146.

    , , & Broad-range PCR/electrospray ionization time-of-flight mass spectrometry for the detection of bacteremia and fungemia in patients with neutropenic fever. J. Clin. Microbiol. 54, 2513–2520 (2016).

  147. 147.

    et al. The IRIDICA BAC BSI assay: rapid, sensitive and culture-independent identification of bacteria and Candida in blood. PLoS ONE 11, 1–16 (2016).

  148. 148.

    et al. Evaluation of a commercially developed semiautomated PCR-surface-enhanced Raman scattering assay for diagnosis of invasive fungal disease. J. Clin. Microbiol. 52, 3536–3543 (2014).

  149. 149.

    et al. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin. Microbiol. Infect. 15, 544–551 (2009).

  150. 150.

    , , & Diagnostic performance and therapeutic impact of LightCycler SeptiFast assay in patients with suspected sepsis. Eur. J. Microbiol. Immunol. 3, 68–76 (2013).

  151. 151.

    et al. Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J. Clin. Microbiol. 47, 2405–2410 (2009).

  152. 152.

    et al. Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J. Clin. Microbiol. 48, 3510–3516 (2010).

  153. 153.

    et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin. Infect. Dis. 60, 875–880 (2015).

  154. 154.

    et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin. Microbiol. Infect. 19, E343–E353 (2013).

  155. 155.

    et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J. Antimicrob. Chemother. 70, 2362–2368 (2015).

  156. 156.

    , , , & Performance evaluation of the T2Candida panel in the ICU setting – data from an ongoing study (Poster). ASM Microbe 2016(2016).

  157. 157.

    , , & Cost-effectiveness analysis of multiplex PCR with magnetic resonance detection versus empiric or blood culture-directed therapy for management of suspected candidemia. J. Clin. Microbiol. 54, 718–726 (2016).

  158. 158.

    CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard — third edition. CLSI (2008).

  159. 159.

    et al. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin. Microbiol. Infect. 22, 571.e1–571.e4 (2016).

  160. 160.

    CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI (2012).

  161. 161.

    , , & Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Updat. 16, 81–95 (2013). This study provides a basic understanding of antifungal susceptibility testing and interpretation.

  162. 162.

    & Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56, 3965–3968 (2012).

  163. 163.

    , , , & Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob. Agents Chemother. 57, 177–182 (2013).

  164. 164.

    et al. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the sensititre yeastone colorimetric method. Antimicrob. Agents Chemother. 59, 6725–6732 (2015).

  165. 165.

    et al. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob. Agents Chemother. 58, 1897–1906 (2014).

  166. 166.

    , , , & Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit. Care Med. 33, 1928–1935 (2005).

  167. 167.

    et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. 233, 542–548 (2001).

  168. 168.

    et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin. Infect. Dis. 58, 1219–1226 (2014).

  169. 169.

    et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann. Intern. Med. 149, 83–90 (2008).

  170. 170.

    et al. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin. Infect. Dis. 61, 1671–1678 (2015).

  171. 171.

    et al. AmarCAND2 Study Group. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. Clin. Microbiol. Infect. 23, 117.e1–117.e8 (2017).

  172. 172.

    , , , & Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. J. Crit. Care. 30, 715–720 (2015).

  173. 173.

    et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit. Care Med. 34, 730–737 (2006).

  174. 174.

    et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54, 46–51 (2011).

  175. 175.

    et al. Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case-control study. Mycoses 56, 664–671 (2013).

  176. 176.

    et al. A nosocomial outbreak of Candida parapsilosis in southern Sweden verified by genotyping. Scand. J. Infect. Dis. 41, 135–142 (2009).

  177. 177.

    et al. Microsatellite multilocus genotyping clarifies the relationship of Candida parapsilosis strains involved in a neonatal intensive care unit outbreak. Diagn. Microbiol. Infect. Dis. 71, 59–62 (2011).

  178. 178.

    et al. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr. Infect. Dis. J. 14, 776–781 (1995).

  179. 179.

    et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol. 43, 2729–2735 (2005).

  180. 180.

    et al. Reporting an outbreak of Candida pelliculosa fungemia in a neonatal intensive care unit. J. Microbiol. Immunol. Infect. 46, 456–462 (2013).

  181. 181.

    et al. Endemic genotypes of Candida albicans causing fungemia are frequent in the hospital. J. Clin. Microbiol. 51, 2118–2123 (2013).

  182. 182.

    et al. Clusters of patients with candidaemia due to genotypes of Candida albicans and Candida parapsilosis: differences in frequency between hospitals. Clin. Microbiol. Infect. 21, 677–683 (2015).

  183. 183.

    , , , Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin. Infect. Dis. 541739–1746 (2012).

  184. 184.

    et al. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS One 11, e0153247 (2016).

  185. 185.

    et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54, 1110–1122 (2012). This patient-level systematic review of randomized trials for candidaemia and invasive candidiasis identifies the important role of echinocandins for primary therapy.

  186. 186.

    et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356, 2472–2482 (2007).

  187. 187.

    et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366, 1435–1442 (2005).

  188. 188.

    et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect. Dis. 14, 97 (2014).

  189. 189.

    et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45 883–893 (2007).

  190. 190.

    et al. Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial [abstract 1239]. ECCMID (2016).

  191. 191.

    et al. CANDIPOP project; GEIH-GEMICOMED (SEIMC); REIPI. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin. Infect. Dis. 58, 1413–1421 (2014).

  192. 192.

    et al. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: analysis of pooled data from six prospective clinical studies. Mycoses 60, 663–667 (2017).

  193. 193.

    et al. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses study group (MSG-12). J. Antimicrob. Chemother. 71, 3536–3539 (2016).

  194. 194.

    et al. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J. Antimicrob. Chemother. 72, 2368–2377 (2017).

  195. 195.

    et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 369, 1519–1527 (2007).

  196. 196.

    et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55, 532–538 (2011).

  197. 197.

    et al. Performance of candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin. Infect. Dis. 54, 1240–1248 (2012).

  198. 198.

    et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5, e1000703 (2009).

  199. 199.

    , & Immunotherapy – a potential adjunctive treatment for fungal infection. Curr. Opin. Infect. Dis. 27, 511–6206 (2014).

  200. 200.

    et al. Changing epidemiology of candidaemia in Australia. J. Antimicrob. Chemother. 72, 1103–1108 (2017).

  201. 201.

    et al. Epidemiology and microbiologic characterization of nosocomial Candidemia from a Brazilian national surveillance program. PLoS ONE 11, e0146909 (2016).

  202. 202.

    et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can. J. Infect. Dis. Med. Microbiol. 19, 55–62 (2008).

  203. 203.

    et al. Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern. J. Clin. Microbiol. 56, e01564-17 (2018).

  204. 204.

    et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med. 43, 652–662 (2017).

  205. 205.

    et al. Distribution of Candida species isolated from blood cultures in hospitals in Osaka, Japan. J. Infect. Chemother. 20, 558–562 (2014).

  206. 206.

    et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).

  207. 207.

    et al. Inhibition of CBLB protects from lethal Candida albicans sepsis. Nat. Med. 22, 915–923 (2016).

  208. 208.

    et al. Inflammatory Ly6Chigh monocytes protect against candidiasis through IL-15-driven NK cell/neutrophil activation. Immunity 46 1059–1072 (2017).

  209. 209.

    et al. The homozygous CX3CR1-M280 mutation impairs human monocyte survival. JCI Insight 3, 95417 (2018).

  210. 210.

    et al. JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. Nat. Med. 23, 337–346 (2017).

  211. 211.

    et al. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob. Agents Chemother. 57, 177–182 (2013).

Download references


This work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health.

Author information


  1. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.

    • Peter G. Pappas
  2. Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.

    • Michail S. Lionakis
  3. Unit for Mycology, Statens Serum Institute, Copenhagen, Denmark.

    • Maiken Cavling Arendrup
  4. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.

    • Maiken Cavling Arendrup
  5. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

    • Maiken Cavling Arendrup
  6. Division of Infectious Diseases, University of Texas Health Science Center, Houston, TX, USA.

    • Luis Ostrosky-Zeichner
  7. Department of Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.

    • Bart Jan Kullberg


  1. Search for Peter G. Pappas in:

  2. Search for Michail S. Lionakis in:

  3. Search for Maiken Cavling Arendrup in:

  4. Search for Luis Ostrosky-Zeichner in:

  5. Search for Bart Jan Kullberg in:


Introduction (P.G.P.); Epidemiology (M.C.A. and L.O.-Z.); Mechanisms/pathophysiology (M.S.L. and M.C.A.); Diagnosis, screening and prevention (M.C.A.); Management (P.G.P. and B.J.K.); Quality of life (P.G.P.); Outlook (B.J.K.); Overview of Primer (P.G.P.).

Competing interests

P.G.P. has received research grants from Merck, Gilead, Astellas, Cidara, IMMY Diagnostics, T2 Biosystems and Mayne Pharma and is a scientific adviser for Cidara, IMMY, Matinas, Amplyx and Mayne Pharma. He is not affiliated with any speakers’ bureau and owns no equities in pharmaceutical companies. M.C.A. has received research grants, payment for contract work on minimum inhibitory concentrations and/or lecture honoraria from the following companies: Merck, Astellas, Basilea, Pfizer, Gilead, Cidara, Amplyx, F2G, Novabiotics and T2Biosystems. She is not affiliated with any speakers’ bureau and owns no equities in pharmaceutical companies. L.O.-Z. has received research grants, consulting honoraria and/or lecture honoraria from the following companies: Merck, Astellas, Pfizer, Gilead, Scynexis, Cidara, Amplyx and Vical. B.J.K. is a scientific adviser for Amplyx, Astellas, Basilea, Cidara and Scynexis. He is not affiliated with any speakers’ bureau and owns no equities in pharmaceutical companies. M.S.L. declares no competing interests.

Corresponding author

Correspondence to Peter G. Pappas.

About this article

Publication history



Further reading